Related Experiment Videos
[Serum levels of beta 2-microglobulin in various types of hemodialysis]
Abstract:
beta 2-microglobulin (beta 2 m) is the major constituent of amyloid fibrils in dialysis-related amyloidosis (DRA), which is considered to be one of the most severe adverse effect of long-term dialysis. In this study we evaluated the efficiency of beta 2 m removal during different dialysis procedures. A total of 45 patients undergoing hemodialysis were divided in five groups: cuprophane dialysis (n = 10), high-flux polysulphone dialysis (n = 10), postdilutional hemodiafiltration (n = 10), conventional postdilutional hemofiltration (n = 10) and predilutional on-line hemofiltration (n = 5). Serum level of beta 2 m was determined before and after different procedures using ELISA. In the group of patients on cuprophane dialysis was registered an elevation of beta 2 m and of 16.8 +/- 11.4% on the average. Serum level of beta 2 m was decreased following all other procedures on the average of 40.7 +/- 16.4% after high-flux polysulphone dialysis, 42.0 +/- 13.7% after conventional hemofiltration, 64.7 +/- 9% after hemodiafiltration and 67.9 +/- 10.1% after predilutional hemofiltration. The best removal of serum beta 2 m was realized by predilutional hemofiltration. Also, we have noticed that patients treated with high-flux synthetic membranes in the longer time-period have lower predyalisis value of beta 2 m compared to patients treated with cuprophane membrane. Further long-term studies will be necessary to conclude whether these procedures could be successful prophylactic and/or therapeutic regimen for dialysis-related amyloidosis.
Insights
Dialysis-related amyloidosis (DRA) is a severe complication linked to beta 2-microglobulin (beta 2 m) buildup. Predilutional hemofiltration demonstrated the most effective removal of beta 2 m, suggesting potential benefits for DRA management.
Area of Science:
- Nephrology
- Biochemistry
- Medical Technology
Context:
- Dialysis-related amyloidosis (DRA) is a serious complication of long-term dialysis.
- Beta 2-microglobulin (beta 2 m) is the primary component of amyloid fibrils in DRA.
- Efficient removal of beta 2 m is crucial for managing DRA.
Purpose:
- To evaluate the efficacy of different dialysis procedures in removing beta 2-microglobulin (beta 2 m).
- To compare beta 2 m clearance across various hemodialysis, high-flux polysulphone dialysis, hemodiafiltration, and hemofiltration techniques.
Summary:
- A study involving 45 hemodialysis patients assessed beta 2 m removal using five procedures: cuprophane dialysis, high-flux polysulphone dialysis, postdilutional hemodiafiltration, conventional postdilutional hemofiltration, and predilutional on-line hemofiltration.
- Cuprophane dialysis showed an average increase in beta 2 m, while other methods decreased levels: high-flux polysulphone (40.7%), conventional hemofiltration (42.0%), hemodiafiltration (64.7%), and predilutional hemofiltration (67.9%).
- Predilutional hemofiltration achieved the highest beta 2 m removal. Patients on high-flux synthetic membranes long-term had lower pre-dialysis beta 2 m levels compared to those on cuprophane.
Impact:
- Predilutional hemofiltration is the most effective method for reducing serum beta 2 m levels among the tested procedures.
- Long-term use of high-flux synthetic membranes may be associated with lower baseline beta 2 m.
- Further research is needed to confirm the prophylactic and therapeutic potential of these procedures for dialysis-related amyloidosis.